Open Access
Table 2.
Comparative analysis of the level of chemokines in children with ALL depending on the development of chemo-induced neurological disorders, M±m.
| Groups | Group 1 (n=9) patients without neurological disorders | Group 2 (n=14) patients with neurological disorders |
|---|---|---|
| Index × pg/ml | ||
| CXCL1(GRO-α) | 175,80±85,26 | 70,96±8,48 |
| CXCL8 (IL-8) | 79,58±31,34 | 39,55±9,96 |
| CXCL10 (IP-10) | 142,01±29,12 | 288,86±47,91* |
| CXCL12 (SDF-1α) | 1562,75±166,43 | 1721,41±103,35* |
| CCL2 (MCP-1) | 474,92±170,91 | 415,50±88,91 |
| CCL3 (MIP-1α) | 16,91±2,07 | 16,56±2,09 |
| CCL4 (MIP-1β) | 56,30±12,97 | 59,18±9,08 |
| CCL5 (RANTES) | 517,68±79,06 | 518,31±65,45 |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.